Track market-moving stories before they get noisy

Key Takeaways Abbott won FDA approval for TactiFlex Duo, an AFib catheter offering PFA, RF energy or both. Abbott's Electrophysiology sales rose 13.4% year over year in the second quarter of 2026. TactiFlex Duo approval was based on FlexPulse IDE data showing favorable safety and effectiveness. Abbott Laboratories (ABT - Free Report) recently received Food and Drug Administration (“FDA”) approval for the TactiFlex Duo Ablation Catheter to treat patients with atrial fibrillation (AFib). TactiFlex Duo represents an important advancement as the company builds the industry's most comprehensive electrophysiology portfolio. 

Abbott will begin cases with broader commercial adoption across the country in the coming weeks.

Predicting ABT Stock Movement Following the NewsFollowing the announcement, ABT’s shares edged down 2.6%, finishing at $105.52 yesterday. 

In recent years, electrophysiology has rapidly evolved as physicians adopt new technologies that improve the safety and effectiveness of AFib treatment. In the second quarter of 2026, Abbott’s Electrophysiology sales grew 13.4% year over year. We expect the latest FDA approval to drive positive market sentiment for ABT stock in the coming days.

Abbott has a market capitalization of $187.45 billion. The company’s earnings yield of 5.1% compares favorably with the industry’s 2.5%. In the trailing four quarters, it delivered an average earnings surprise of 0.8%. 

About ABT’s TactiFlex DuoTactiFlex Duo is the company’s latest ablation catheter designed to give physicians more flexibility when treating AFib. The technology allows physicians to use pulsed field ablation (PFA), radiofrequency (RF) energy or a combination of both during a procedure, helping them tailor treatment to each patient's needs. 

Abbott's EnSite X EP system provides physicians with real-time feedback and integrates the PFA Index, a tool designed to assess lesion formation during ablation with TactiFlex Duo. The dual-energy approach helps create precise therapeutic lesions or small areas of scar tissue that block the abnormal electrical signals causing an irregular heartbeat while minimizing the impact on surrounding healthy tissue. 

More Information on the FDA ApprovalThe FDA approval of TactiFlex Duo expands Abbott's portfolio of technologies designed to help physicians treat patients with cardiac arrhythmias. The approval was secured based on the results from Abbott's FlexPulse IDE study. Late-breaking data from the study showed favorable safety and effectiveness outcomes in patients with paroxysmal AFib (irregular heart rhythm episodes that come and go).

Industry Prospects Favor ABTPer a report by Research Nester, the cardiac ablation market size was valued at $5.50 billion in 2025 and is set to exceed $17.86 billion by 2035, registering a CAGR of more than 12.5% during the forecast period (2026-2035). In 2026, the cardiac ablation market is estimated at $6.12 billion.

Image Source: Zacks Investment Research

Another Recent Development by ABTAbbott launched Similac 360 Total Care Made With Whole Milk, the first and only commercially sterile, ready-to-feed liquid infant formula made with whole milk in the United States. Its fat blend more closely resembles the fats in breast milk and it contains five immune-nourishing prebiotics to help support a baby's natural defenses. The product joins the company’s extensive portfolio of infant formulas.  

ABT Stock Price PerformanceOver the past year, ABT’s shares have plunged 20.1% compared with the industry’s 26.9% decline.

ABT’s Zacks Rank & Key PicksAbbott currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and Illumina (ILMN - Free Report) .

Globus Medical has an earnings yield of 5.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED’s shares have rallied 42.3% against the industry’s 6.3% decline over the past year.

GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Veracyte, sporting a Zacks Rank #1 at present, has an earnings yield of 4.6% against the industry’s negative 1.7% yield. Shares of the company have risen 38% against the industry’s 6.3% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, with the average surprise being 41.8%. 

Illumina, presently carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 13% compared with the industry’s 23% rise. Its earnings beat estimates in each of the trailing four quarters, with the average surprise being 9.7%. ILMN’s shares have rallied 194.6% compared with the industry’s 24.6% growth over the past year.

Israel Englander is a famous and successful hedge fund manager who founded Millennium Management. This hedge fund firm has delivered excellent returns over the past few decades, so it is worth taking a look inside its portfolio. During the second quarter, Izzy Englander and his team made several notable purchase decisions, including increasing their stakes in two dividend-paying companies: AbbVie (ABBV -3.00%) and Costco (COST -0.61%). The firm more than doubled its position in both stocks. Should retail investors follow suit?

Image source: The Motley Fool.

1. AbbVie AbbVie has faced challenges in recent years, including a major patent cliff and clinical setbacks that have weighed on the stock. Somehow, the company always manages to bounce back. AbbVie's shares have moved in line with the S&P 500 this year, and they may continue doing so -- and perhaps even outpace broader equities -- over the medium term. Consider several reasons why. First, AbbVie's core business is rock-solid.

The company's two growth pillars, the immunology medicines Skyrizi and Rinvoq, are doing much of the heavy lifting. In the second quarter, AbbVie's revenue grew by 10.2% year over year to about $17 billion. Sales from Skyrizi and Rinvoq grew much faster than that, lifting the company's average. Neither medicine will lose patent exclusivity until the next decade, so they still have plenty of growth fuel left. And it's also worth noting that AbbVie has no remaining significant patent cliff through the end of the current decade.

Premium Feature

Moneyball Superscore

79/100

Today's Change

(

-3.00

%) $

-7.68

Current Price

$

248.78

Second, AbbVie has a deep pipeline with several products that could become blockbusters. One of them is ABBV-295, an investigational long-acting weight-loss candidate. ABBV-295 is an interesting product that could carve out a niche in the fast-growing anti-obesity market, as it could be administered monthly and address the need for weight-loss options with fewer adverse events. ABBV-295 is still in early-stage studies. There is a long road ahead before it can hope to earn approval.

But ABBV-295 is only the tip of the iceberg when it comes to AbbVie's pipeline. Consider the company's recent acquisition of Apogee Therapeutics for $10.9 billion in cash. Apogee brings a highly promising phase 3 asset, zumilokibart, under development for atopic dermatitis. Zumilokibart could have the advantage of being administered less frequently than current medicines in this area while sacrificing little in efficacy. AbbVie still has to demonstrate that in phase 3 studies, but this is a candidate that could help solidify its position in the immunology market.

Third, AbbVie is a fantastic dividend stock. When including the time it spent as a division of Abbott Laboratories (ABT -2.59%), the company is a Dividend King, or a corporation with 50 -- or more -- consecutive years of payout increases. Reinvesting dividends can significantly boost long-term returns, particularly with a stock that consistently grows its payouts like AbbVie does. That's another reason the company may outperform broader equities, and is worth investing in today for long-term, income-seeking investors.

2. Costco Costco has faced a fairly volatile environment this year. Soaring gas prices and other macro headwinds have weighed on the company's business. Meanwhile, the stock remains fairly expensive. Costco is trading at 40.8x forward earnings, versus an average of 21.6x for consumer staples stocks. Investors are willing to pay a premium for Costco, so long as the business remains healthy.

But like always, expensive stocks can decline meaningfully at any sign of trouble, and that's what has happened to the retail giant. Costco's shares are down 4% over the past year, while the S&P 500 has gained 19%. That said, Costco's financial resuls has proved fairly resilient despite the headwinds it is facing.

Premium Feature

Moneyball Superscore

81/100

Today's Change

(

-0.61

%) $

-5.56

Current Price

$

910.18

In the third quarter of the company's fiscal year 2026 (its period that ended on May 10), Costco's revenue grew by 11.6% year over year to $70.5 billion. Comparable sales rose 9.8%, while the company's earnings per share were $4.93, up 15% versus the comparable period of the previous fiscal year. Costco may remain somewhat volatile in the short run as it navigates an uncertain environment, but there is a lot to like about the company's long-term prospects.

Costco's subscription business model provides a high-margin, recurring revenue stream and a powerful incentive for customers to keep shopping in its stores to get their money's worth from their subscriptions. That alone grants the company a solid competitive advantage. It also has a strong e-commerce business that should help lift profits and margins over the long run. Then there is the dividend. Costco has raised its payouts for 22 consecutive years.

That's not close to Dividend King status, but it's still impressive. Despite Costco's low 0.6% forward yield, the company is a solid income stock to hold onto for a while. I'd follow Israel Englander's lead on this one.

Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ combines pulsed field ablation (PFA) and radiofrequency (RF) energy in a single catheter to treat complex atrial fibrillation (AFib) cases Strong clinical evidence demonstrates the device's high rates of safety and effectiveness in treating AFib patients FDA approval of TactiFlex Duo strengthens Abbott's expanding PFA portfolio following recent cardiac ablation approvals in the U.S., Europe, Asia and Latin America , /PRNewswire/ -- Abbott, the global healthcare leader, announced today it has received U.S. Food and Drug Administration (FDA) approval for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ to treat patients with challenging cases of atrial fibrillation (AFib). The U.S. approval of this dual-energy catheter, the latest generation of Abbott's cardiac ablation technology, marks a significant milestone in Abbott's commitment to advancing therapies that help physicians treat complex heart rhythms with greater precision and flexibility. Abbott will soon begin cases with broader commercial adoption across the country in the coming weeks.

Why cardiac ablation matters for people with AFib
For the 10.5 million people in the U.S. who live with a heart that beats too fast, too slow or in an irregular way, treatment is critical as AFib increases the risk of serious complications, including stroke.1,2 While many people are treated with medications, others require cardiac ablation, a minimally invasive procedure that targets the tissue responsible for abnormal electrical signals in the heart.

TactiFlex Duo is Abbott's latest ablation catheter designed to give physicians more flexibility when treating AFib. The technology allows physicians to use pulsed field ablation (PFA), radiofrequency (RF) energy, or a combination of both during a procedure, helping them tailor treatment to each patient's needs. Abbott's EnSite™ X EP System also provides physicians with real-time feedback as an integrated mapping solution with the PFA Index (PI), a tool designed to assess lesion formation during ablation with TactiFlex Duo. The dual-energy approach means physicians can create precise therapeutic lesions, or small areas of scar tissue, that block the abnormal electrical signals causing an irregular heartbeat while helping minimize the impact on surrounding healthy tissue. Successfully treating these areas can help restore the heart's normal rhythm and improve outcomes for patients living with AFib. 

"Electrophysiology is rapidly evolving as physicians adopt new technologies that improve the safety and effectiveness of AFib treatment," said Atul Verma, M.D., Director of Cardiology at the McGill University Health Centre in Montreal, Canada, and a globally recognized expert in pulsed field ablation technology. "TactiFlex Duo provides physicians with greater flexibility during procedures, and when it is combined with the high-resolution 3D visualization available through Abbott's EnSite X mapping system, physicians have a suite of practice-changing tools to confidently treat patients with complex AFib."

Safety and effectiveness data support TactiFlex Duo FDA approval  
The FDA approval of TactiFlex Duo was secured based on the results from Abbott's FlexPulse IDE study. Late-breaking data from the study recently presented at the European Society of Cardiology (ESC) Congress 2026, which was simultaneously published in EP Europace, showed favorable safety and effectiveness outcomes in patients with paroxysmal AFib (irregular heart rhythm episodes that come and go).

"TactiFlex Duo represents an important advancement as Abbott builds the industry's most comprehensive electrophysiology portfolio," said Uri Yaron, senior vice president of Abbott's electrophysiology business. "From diagnosis, mapping and intracardiac ultrasound imaging to advanced treatments for the most complex arrhythmias, Abbott is uniquely positioned to support physicians at every stage of patient care. By continuing to expand our PFA portfolio and integrate innovative technologies across cardiovascular care, we're helping physicians navigate increasingly complex procedures while ensuring more patients receive the right care at the right time."

Regulatory momentum across Abbott's PFA portfolio
The U.S. FDA approval of TactiFlex Duo further expands Abbott's portfolio of technologies designed to help physicians treat patients with cardiac arrhythmias. It is the company's fifth major electrophysiology approval in just over a year, following Europe's Amulet 360™ and TactiFlex Duo CE Mark approvals this year, and U.S. and European approvals of the Volt™ PFA System in 2025.

Frequently Asked Questions

What is TactiFlex Duo?
TactiFlex Duo is an advanced cardiac ablation catheter designed to treat irregular heart rhythms. Its dual-energy feature combines pulsed field ablation (PFA) and radiofrequency (RF) energy in a single device, allowing physicians to tailor treatment to each patient's unique needs during AFib ablation procedures.  

How do physicians know the precise locations in the heart to treat patients with TactiFlex Duo?  
TactiFlex Duo is integrated with Abbott's EnSite X EP System, a sophisticated mapping system that creates highly detailed three-dimensional maps of the heart to help doctors find and treat the source of an irregular heartbeat. Working together with Abbott's Advisor™ HD Grid X mapping catheter, ViewFlex™X ICE (intracardiac echocardiography) catheter and EnSite Echo Module, the integrated portfolio is designed to give physicians real-time images of the ablation catheter's positioning and movement, and a digital model of the patient's heart throughout a procedure. The EnSite X EP System also provides physicians with real-time information – called PFA index – which shows how the small areas of scar tissue created by TactiFlex Duo's pulsed field energy develop during an ablation procedure.3 

Who may need an ablation using TactiFlex Duo?
Patients with atrial fibrillation, particularly those with complex anatomy, prior or failed ablations or other challenging clinical situations, may benefit from treatment with TactiFlex Duo as determined by their physician. 

What are the patient benefits of being treated with TactiFlex Duo?
The catheter offers physicians greater procedural flexibility and precision through dual-energy capabilities, helping treat irregular heart rhythms while reducing the potential for damage to surrounding tissue. Clinical data has shown the technology to be safe and effective.

For U.S. important safety information go to:

TactiFlex Duo Ablation Catheter, Sensor Enabled

Volt™ PFA System

EnSite™ X EP System 

Advisor HD Grid X Mapping Catheter, Sensor Enabled™

ViewFlex X ICE Catheter, Sensor Enabled™ and EnSite Echo Module

The Amulet 360™ Left Atrial Appendage Occluder is approved for investigational use only in the U.S.

About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic 3 medicines. Our 122,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube. 

________________________________

1 Noubiap JJ, Tang JJ, Teraoka JT, Dewland TA, Marcus GM. Minimum National Prevalence of Diagnosed Atrial Fibrillation Inferred From California Acute Care Facilities. J Am Coll Cardiol. 2024;84(16):1501-1508. doi:10.1016/j.jacc.2024.07.014.

2 About Atrial Fibrillation. Centers for Disease Control. (n.d.). About Atrial Fibrillation | Heart Disease | CDC.

3 Friedman, et al. (2025 September) Development of a PFA index to guide energy delivery with a force sensing flexible, irrigated tip catheter [Oral presentation]. ESC 2025, Madrid, Spain.

SOURCE Abbott

With doubts around geopolitical issues combined with the stock market trading near record highs, it's natural to wonder whether a painful sell-off is overdue. If it is, Abbott Laboratories (ABT -0.42%) could be one of the best dividend stocks to own through the storm. Abbott is a Dividend King, a company that has increased its dividend for at least 50 consecutive years. In Abbott's case, it has raised its dividend for the past 54 consecutive years.

If the market crashes, Abbott could provide investors with a stable income stream, helping to soften the blow as they wait for a recovery.

The bigger question now is whether Abbott can keep it going.

Image source: Getty Images.

Abbott's dividend looks sustainable, even in a slowdown In the second quarter, the company reported sales of $12.6 billion, up 13% year over year, while adjusted diluted earnings per share (EPS) came in at $1.31, beating Wall Street expectations. Management is confident that momentum can continue, as the company raised its full-year adjusted EPS forecast to between $5.45 and $5.60 per share.

Meanwhile, Abbott's dividend payout ratio is about 46%, meaning the company pays out less than half of its earnings as dividends. For dividend investors, that means Abbott earns more than enough to keep paying shareholders while still leaving room to reinvest in the business. And the more the business grows, the more it can support future dividend increases.

In fact, Abbott returned $2.1 billion to shareholders in the second quarter alone through a combination of share repurchases and dividends. Today, the stock's forward dividend yield is roughly 2.3%.

So, can Abbott keep increasing its dividends?

Premium Feature

Moneyball Superscore

74/100

Today's Change

(

-0.42

%) $

-0.46

Current Price

$

108.33

New products and a major deal could lift growth in 2026 Management believes sales and earnings will accelerate in the second half of 2026, creating a favorable setup for continued dividend increases. Abbott's medical devices business has been one of its bright spots.

The segment is seeing solid growth thanks to the U.S. launch of the Volt PFA system and the international rollout of Volt and TactiFlex Duo, devices used to treat certain heart conditions.

But perhaps the biggest catalyst this year was Abbott's $21 billion acquisition of Exact Sciences. With the deal, Abbott is expanding into the fast-growing cancer diagnostics market. Granted, the acquisition closed only in March, so there is still plenty of runway ahead, especially as the new business contributes more to earnings.

Investors are already seeing promising signs that this investment is paying off. Revenue in Abbott's cancer diagnostics segment grew 13.3% in the second quarter, driven by precision oncology, international growth, and Cologuard, a noninvasive colorectal cancer screening test.

Looking ahead, this segment is well-positioned to deliver stronger growth in the second half of the year, especially as Abbott ramps up newly launched tests, care gap programs, and overseas expansion.

So, what do analysts think about Abbott stock?

Should dividend investors consider buying Abbott now? For dividend investors who own Abbott, the appeal is a compelling combination of income and stability. The company has raised its dividend for more than five decades, and its latest results prove that earnings and cash flow can support future payouts.

At the same time, Abbott's medical devices and cancer diagnostics businesses provide clear avenues for growth. If those segments continue to expand and generate cash, they could give Abbott an even stronger cushion to maintain and potentially raise its dividend, even if the broader market stumbles.

Wall Street appears bullish, with analyst offering "strong buy" rating on average. If a crash happens, investors will likely want holdings that can keep paying them while they wait it out, and Abbott Laboratories fits that profile.

A. D. Beadell Investment Counsel Inc. increased its position in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 28.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 34,819 shares of the healthcare product maker’s stock after buying an additional 7,722 shares during the quarter. Abbott Laboratories accounts for 2.0% of A. D. Beadell Investment Counsel Inc.’s portfolio, making the stock its 17th biggest holding. A. D. Beadell Investment Counsel Inc.’s holdings in Abbott Laboratories were worth $3,159,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently modified their holdings of the company. Headlands Technologies LLC increased its holdings in Abbott Laboratories by 74.3% in the second quarter. Headlands Technologies LLC now owns 40,367 shares of the healthcare product maker’s stock valued at $3,663,000 after purchasing an additional 17,203 shares during the last quarter. Sigma Planning Corp boosted its holdings in shares of Abbott Laboratories by 1.2% in the 2nd quarter. Sigma Planning Corp now owns 13,495 shares of the healthcare product maker’s stock valued at $1,225,000 after buying an additional 154 shares during the last quarter. Alyeska Investment Group L.P. acquired a new position in shares of Abbott Laboratories during the 2nd quarter worth about $106,717,000. Flputnam Investment Management Co. increased its position in Abbott Laboratories by 9.7% during the second quarter. Flputnam Investment Management Co. now owns 84,829 shares of the healthcare product maker’s stock worth $7,697,000 after buying an additional 7,469 shares during the last quarter. Finally, Davidson Investment Advisors raised its stake in Abbott Laboratories by 3.6% in the 2nd quarter. Davidson Investment Advisors now owns 3,084 shares of the healthcare product maker’s stock valued at $280,000 after acquiring an additional 106 shares during the period. Institutional investors own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades Several research analysts have weighed in on the company. Royal Bank Of Canada reiterated an “outperform” rating and set a $130.00 price objective on shares of Abbott Laboratories in a research report on Friday, July 17th. Wolfe Research raised Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price target for the company in a report on Thursday, August 13th. JPMorgan Chase & Co. boosted their price target on Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. Piper Sandler reaffirmed an “overweight” rating and issued a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Finally, Weiss Ratings raised Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, August 6th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $119.50.

Read Our Latest Report on Abbott Laboratories Abbott Laboratories Stock Performance NYSE ABT opened at $108.29 on Friday. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The stock has a market capitalization of $187.38 billion, a PE ratio of 35.05, a P/E/G ratio of 2.02 and a beta of 0.59. The company’s 50 day simple moving average is $104.43 and its two-hundred day simple moving average is $100.12.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. During the same quarter last year, the company posted $1.26 EPS. The business’s quarterly revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend The firm also recently declared a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were paid a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.3%. Abbott Laboratories’s payout ratio is currently 81.55%.

Abbott Laboratories Profile (Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Featured Stories Five stocks we like better than Abbott Laboratories Revolution Medicines Got Its Breakthrough—What Moves It Next? Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism AST SpaceMobile Stock Soared 12%—This Was the Catalyst

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

The best investing strategies aren't always the most complicated ones. Sometimes, simply buying great dividend stocks and holding them for the long term is the smartest approach you can take.

Of course, you have to find the right stocks. While there are many great candidates, here are three dividend stocks that I think are great picks to buy and hold forever.

Image source: Getty Images.

1. AbbVie Perhaps the most important thing to know about AbbVie (ABBV -1.44%) is that it's a Dividend King. This elite group of companies have increased their dividends for at least 50 consecutive years. AbbVie's track record of dividend hikes spans 53 straight years, including the period when it was part of Abbott Labs (ABT -0.42%).

Inclusion in the Dividend Kings usually means that a company has a remarkably resilient underlying business. That's definitely the case with AbbVie. Its roots date back to 1888. The company has survived and thrived throughout its 138-year history despite facing stiff challenges.

Premium Feature

Moneyball Superscore

79/100

Today's Change

(

-1.44

%) $

-3.75

Current Price

$

256.46

One of AbbVie's biggest challenges was the patent expiration for Humira, which ranked for years as its top-selling product. But management planned well for the loss of exclusivity. Today, AbbVie has two successors to Humira -- Skyrizi and Rinvoq -- that together are already more successful than Humira was at its peak.

AbbVie's business development strategy has also been effective. Most recently, the company announced plans to acquire Apogee Therapeutics for $10.9 billion. This deal further expands AbbVie's immunology pipeline.

2. Enbridge Enbridge (ENB -0.85%) isn't a Dividend King yet, but it's well on the way to joining the club. The energy company has increased its dividend for 31 consecutive years. And with a dividend yield of around 5.6%, Enbridge doesn't need to deliver tremendous share price appreciation to deliver a double-digit total return.

I think such attractive returns are likely going forward. Four key trends serve as big growth drivers for Enbridge: the surging build-out of data centers, rising demand for liquid natural gas (LNG), onshoring, and the conversion of power plants from coal to gas.

Premium Feature

Moneyball Superscore

76/100

Today's Change

(

-0.85

%) $

-0.43

Current Price

$

50.09

Enbridge forecasts a compound annual growth rate of around 5% for its distributable cash flow, earnings per share, and earnings before interest, taxes, depreciation, and amortization (EBITDA). As long as the company's dividends continue to flow at least at current levels, double-digit total returns should be attainable.

Fortunately for investors, Enbridge's business stability should make the dividend safe. The company operates the world's longest oil and liquids transportation system, with its pipelines transporting 40% of U.S. crude oil imports and 30% of crude oil produced in North America. It's also North America's largest natural gas utility by volume.

3. Realty Income Speaking of business stability, the third dividend stock on our list ranks highly in this category. Realty Income (O -0.79%) shares have outperformed the S&P 500 (SNPINDEX:^GSPC) across 13 drawdowns of 10% or more since its public listing in 1994, with an average total return of -2.6% versus -22.6% for the S&P 500.

The real estate investment trust (REIT) has also increased its dividend for 31 consecutive years. And it has paid a dividend for 674 consecutive months.

Premium Feature

Moneyball Superscore

84/100

Today's Change

(

-0.79

%) $

-0.49

Current Price

$

61.25

What's behind Realty Income's remarkable record? A diversified real estate portfolio serves as a key factor. The REIT owns over 15,500 properties leased to clients representing 92 industries. Those industries include recession-resistant ones, such as grocery stores, convenience stores, and dollar stores.

Realty Income's growth prospects look bright, too. The company has a $15 trillion total addressable market. Around $9 billion of this total addressable market is in Europe, which has a highly fragmented market that offers attractive risk-adjusted returns.

49 Wealth Management LLC bought a new stake in Abbott Laboratories (NYSE:ABT – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 6,680 shares of the healthcare product maker’s stock, valued at approximately $606,000.

A number of other hedge funds also recently bought and sold shares of the business. MidAtlantic Capital Management Inc. purchased a new position in shares of Abbott Laboratories in the 4th quarter worth $25,000. Cornerstone Financial Management LLC purchased a new stake in shares of Abbott Laboratories during the 4th quarter valued at about $25,000. Purpose Unlimited Inc. bought a new position in shares of Abbott Laboratories in the 4th quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in Abbott Laboratories in the fourth quarter worth about $26,000. Finally, Abound Financial LLC purchased a new position in Abbott Laboratories in the fourth quarter worth about $26,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Price Performance ABT opened at $108.81 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The business has a fifty day moving average of $104.14 and a 200 day moving average of $100.06. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $137.49. The stock has a market cap of $188.28 billion, a P/E ratio of 35.21, a PEG ratio of 2.05 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT – Get Free Report) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. The business had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same period last year, the company earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, sell-side analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current year. Abbott Laboratories Announces Dividend The business also recently announced a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is currently 81.55%.

Abbott Laboratories News Roundup Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: Abbott shares outperformed the broader market in the latest session, suggesting continued investor support for the diversified healthcare-products company. The move adds to its gains above both its 50-day and 200-day moving averages. Abbott Exceeds Market Returns: Some Facts to Consider Neutral Sentiment: A separate market comparison reported that Abbott underperformed its competitors during Tuesday’s trading session. The article did not identify a company-specific operational problem, making the relative weakness more relevant to short-term sentiment than to Abbott’s long-term fundamentals. Abbott Laboratories Stock Underperforms Tuesday Neutral Sentiment: Vice President John McCoy Jr. sold 27 shares for approximately $2,958. The transaction reduced his direct holdings by only 0.11%, leaving him with 24,549 shares, so it is too small to represent a meaningful change in insider conviction. SEC Insider Transaction Filing Neutral Sentiment: An investor-focused healthcare article mentioned Abbott primarily as the former parent of AbbVie, rather than discussing new developments at ABT. It therefore provides little direct information about Abbott’s near-term earnings or valuation. Abbott Laboratories Company Information Analyst Upgrades and Downgrades Several equities research analysts have recently issued reports on the company. UBS Group lowered their price objective on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Wells Fargo & Company boosted their target price on Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. The Goldman Sachs Group lowered their price target on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research report on Wednesday, May 27th. Weiss Ratings raised shares of Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, August 6th. Finally, TD Cowen boosted their price objective on shares of Abbott Laboratories from $115.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, August 25th. Three analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $119.50.

Check Out Our Latest Analysis on Abbott Laboratories

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Featured Stories Five stocks we like better than Abbott Laboratories The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now Dropping the Dough: Yum! Brands Strategically Trims the Fat These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

In the latest close session, Abbott (ABT - Free Report) was up +1.41% at $110.47. This move outpaced the S&P 500's daily gain of 0.46%. Elsewhere, the Dow gained 0.56%, while the tech-heavy Nasdaq added 0.45%.

The maker of infant formula, medical devices and drugs's shares have seen an increase of 3.29% over the last month, not keeping up with the Medical sector's gain of 4.16% and outstripping the S&P 500's gain of 2%.

The upcoming earnings release of Abbott will be of great interest to investors. In that report, analysts expect Abbott to post earnings of $1.43 per share. This would mark year-over-year growth of 10%. At the same time, our most recent consensus estimate is projecting a revenue of $12.91 billion, reflecting a 13.52% rise from the equivalent quarter last year.

Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $5.52 per share and revenue of $50.32 billion. These totals would mark changes of +7.18% and +13.51%, respectively, from last year.

Investors should also pay attention to any latest changes in analyst estimates for Abbott. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.03% higher. Right now, Abbott possesses a Zacks Rank of #3 (Hold).

In the context of valuation, Abbott is at present trading with a Forward P/E ratio of 19.73. This signifies a discount in comparison to the average Forward P/E of 21.18 for its industry.

One should further note that ABT currently holds a PEG ratio of 2.02. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As the market closed yesterday, the Medical - Products industry was having an average PEG ratio of 1.88.

The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 97, putting it in the top 40% of all 250+ industries.

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.

Jupiter Topco LLC acquired a new position in shares of Abbott Laboratories (NYSE:ABT – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 8,075,934 shares of the healthcare product maker’s stock, valued at approximately $732,788,000. Jupiter Topco LLC owned approximately 0.47% of Abbott Laboratories as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ABT. Brighton Jones LLC raised its stake in shares of Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after purchasing an additional 4,755 shares during the period. Sivia Capital Partners LLC boosted its position in shares of Abbott Laboratories by 3.5% during the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after buying an additional 162 shares during the period. United Bank grew its holdings in shares of Abbott Laboratories by 7.4% during the second quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock worth $3,945,000 after buying an additional 2,001 shares in the last quarter. Main Street Financial Solutions LLC grew its holdings in shares of Abbott Laboratories by 13.6% during the second quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock worth $1,618,000 after buying an additional 1,428 shares in the last quarter. Finally, Canada Pension Plan Investment Board raised its position in Abbott Laboratories by 25.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock valued at $195,267,000 after buying an additional 292,547 shares during the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Price Performance NYSE:ABT opened at $108.86 on Wednesday. The stock has a market capitalization of $188.37 billion, a PE ratio of 35.23, a P/E/G ratio of 2.05 and a beta of 0.59. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49. The firm has a fifty day simple moving average of $103.43 and a 200 day simple moving average of $100.09. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company’s quarterly revenue was up 13.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, research analysts expect that Abbott Laboratories will post 5.52 EPS for the current fiscal year. Abbott Laboratories Announces Dividend The company also recently announced a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were paid a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.3%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 81.55%.

Abbott Laboratories News Summary Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: New infant formula expands Abbott’s nutrition portfolio. Abbott launched Similac 360 Total Care Made With Whole Milk, described as the first commercially sterile, ready-to-feed liquid whole-milk infant formula available in the U.S. The product targets growing parental interest in whole-milk formulas while offering convenience at a price similar to Similac’s powdered formula. Wider distribution and consumer adoption could provide incremental growth for Abbott’s Nutrition segment. Abbott launches whole-milk liquid infant formula Positive Sentiment: Analysts remain optimistic despite relative underperformance. Coverage notes that ABT has lagged the broader healthcare sector over the past year, but Wall Street analysts continue to express confidence in the company’s outlook. Recent earnings also showed revenue growth, an earnings-per-share beat and reaffirmed 2026 guidance, supporting the bullish view. Abbott stock and healthcare-sector performance Neutral Sentiment: Abbott is positioning the launch around changing consumer and policy preferences. The whole-milk formula introduction aligns with interest in “Make America Healthy Again” themes, but the financial impact will depend on demand, pricing and market share gains. Abbott and the Make America Healthy Again movement Negative Sentiment: Formula-related advertising scrutiny remains a risk. In a challenge brought by Abbott, the National Advertising Division supported certain Kendamil whole-milk claims but recommended that other nutritional, ingredient and heritage claims be modified or discontinued. The decision is not a direct finding against Abbott, but it highlights competitive scrutiny in the infant-formula market. NAD decision on Kendamil infant formula claims Analyst Ratings Changes Several equities analysts have recently weighed in on ABT shares. TD Cowen raised their price target on shares of Abbott Laboratories from $115.00 to $135.00 and gave the stock a “buy” rating in a research note on Tuesday, August 25th. JPMorgan Chase & Co. increased their target price on shares of Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. Citigroup raised their target price on shares of Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a research report on Friday, July 17th. Weiss Ratings upgraded shares of Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, August 6th. Finally, The Goldman Sachs Group reduced their price objective on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research note on Wednesday, May 27th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $119.50.

Check Out Our Latest Research Report on ABT

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Featured Stories Five stocks we like better than Abbott Laboratories Dutch Bros Sell-Off Creates a Growth Opportunity NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat Is Abercrombie & Fitch’s Hot Streak Just Getting Started? Medtronic’s Stars Are Aligning for a Price Recovery Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Abbott Laboratories (NYSE:ABT – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 869,131 shares of the healthcare product maker’s stock, valued at approximately $78,865,000. Connor Clark & Lunn Investment Management Ltd. owned about 0.05% of Abbott Laboratories as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the company. MidAtlantic Capital Management Inc. bought a new position in Abbott Laboratories in the 4th quarter valued at approximately $25,000. Cornerstone Financial Management LLC bought a new stake in Abbott Laboratories during the 4th quarter worth approximately $25,000. Purpose Unlimited Inc. acquired a new position in Abbott Laboratories in the 4th quarter valued at approximately $25,000. Portfolio Resources Advisor Group Inc. bought a new position in shares of Abbott Laboratories during the fourth quarter valued at $26,000. Finally, Abound Financial LLC acquired a new position in shares of Abbott Laboratories during the fourth quarter worth $26,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Stock Performance NYSE:ABT opened at $110.48 on Tuesday. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49. The company has a fifty day moving average of $103.06 and a 200-day moving average of $100.13. The firm has a market capitalization of $191.17 billion, a P/E ratio of 35.75, a P/E/G ratio of 2.18 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The business had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm’s revenue was up 13.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, sell-side analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current year. Abbott Laboratories Dividend Announcement The company also recently announced a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 81.55%.

Wall Street Analyst Weigh In ABT has been the subject of a number of recent research reports. The Goldman Sachs Group decreased their price objective on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a report on Wednesday, May 27th. Bank of America decreased their price target on Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. JPMorgan Chase & Co. upped their target price on Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Piper Sandler reissued an “overweight” rating and set a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Finally, BTIG Research boosted their price target on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $119.50.

Read Our Latest Stock Analysis on ABT

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Read More Five stocks we like better than Abbott Laboratories Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season Insiders Are Betting Big on These 3 Healthcare Stocks 3 Stocks for Investors Who Still Believe Cash Is King Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Elevation Point Wealth Partners LLC bought a new position in Abbott Laboratories (NYSE:ABT – Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 51,158 shares of the healthcare product maker’s stock, valued at approximately $4,642,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Daiichi Life Insurance Co. Ltd. purchased a new position in shares of Abbott Laboratories in the 2nd quarter worth about $9,027,000. Foyston Gordon & Payne Inc purchased a new stake in Abbott Laboratories during the 2nd quarter valued at about $1,107,000. Commerce Bank bought a new stake in Abbott Laboratories during the 2nd quarter valued at about $40,622,000. Northwestern Mutual Wealth Management Co. purchased a new position in Abbott Laboratories in the second quarter worth about $23,165,000. Finally, Quantbot Technologies LP bought a new position in shares of Abbott Laboratories in the second quarter worth approximately $2,900,000. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Price Performance Shares of ABT opened at $110.48 on Tuesday. The firm has a fifty day simple moving average of $103.06 and a two-hundred day simple moving average of $100.13. The firm has a market cap of $191.17 billion, a PE ratio of 35.75, a P/E/G ratio of 2.18 and a beta of 0.59. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49.

Abbott Laboratories (NYSE:ABT – Get Free Report) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The firm had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same period last year, the business posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current year. Abbott Laboratories Dividend Announcement The firm also recently declared a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio is presently 81.55%.

Wall Street Analysts Forecast Growth Several brokerages recently weighed in on ABT. TD Cowen raised their price target on shares of Abbott Laboratories from $115.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, August 25th. Bank of America lowered their price objective on Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Wolfe Research raised Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 target price for the company in a report on Thursday, August 13th. Piper Sandler restated an “overweight” rating and issued a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Finally, JPMorgan Chase & Co. upped their price target on Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $119.50.

View Our Latest Stock Analysis on Abbott Laboratories

Abbott Laboratories Company Profile (Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Featured Stories Five stocks we like better than Abbott Laboratories Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season Insiders Are Betting Big on These 3 Healthcare Stocks 3 Stocks for Investors Who Still Believe Cash Is King Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Haverford Trust Co acquired a new stake in Abbott Laboratories (NYSE:ABT – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 83,252 shares of the healthcare product maker’s stock, valued at approximately $7,554,000.

A number of other hedge funds have also modified their holdings of ABT. BlackRock Inc. raised its position in Abbott Laboratories by 4.6% in the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock valued at $13,843,610,000 after purchasing an additional 6,769,518 shares during the last quarter. State Street Corp grew its position in Abbott Laboratories by 2.1% during the 4th quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker’s stock worth $10,004,880,000 after purchasing an additional 1,627,791 shares during the last quarter. Capital International Investors increased its stake in Abbott Laboratories by 2.6% in the fourth quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock valued at $7,922,519,000 after purchasing an additional 1,614,706 shares during the period. J. Stern & Co. LLP raised its holdings in shares of Abbott Laboratories by 12,439.6% in the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after buying an additional 39,005,451 shares during the last quarter. Finally, Capital Research Global Investors boosted its stake in shares of Abbott Laboratories by 1.0% during the fourth quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker’s stock worth $4,907,523,000 after buying an additional 400,400 shares during the period. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Abbott Laboratories Stock Down 1.8% ABT opened at $110.48 on Tuesday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The company has a market cap of $191.17 billion, a price-to-earnings ratio of 35.75, a PEG ratio of 2.18 and a beta of 0.59. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The business’s fifty day moving average is $103.06 and its two-hundred day moving average is $100.13.

Abbott Laboratories (NYSE:ABT – Get Free Report) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter in the previous year, the company posted $1.26 EPS. The business’s revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current fiscal year. Abbott Laboratories Announces Dividend The firm also recently declared a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were given a $0.63 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio is currently 81.55%.

Wall Street Analyst Weigh In A number of equities analysts recently issued reports on ABT shares. Weiss Ratings raised Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, August 6th. Piper Sandler reaffirmed an “overweight” rating and set a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Bank of America lowered their target price on Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. BTIG Research boosted their target price on Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a report on Friday, July 17th. Finally, Wolfe Research raised Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price target for the company in a report on Thursday, August 13th. Three research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $119.50.

Read Our Latest Stock Report on Abbott Laboratories

Abbott Laboratories Profile (Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Read More Five stocks we like better than Abbott Laboratories Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season Insiders Are Betting Big on These 3 Healthcare Stocks 3 Stocks for Investors Who Still Believe Cash Is King Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Clear Harbor Asset Management LLC bought a new stake in Abbott Laboratories (NYSE:ABT – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 53,874 shares of the healthcare product maker’s stock, valued at approximately $4,889,000.

A number of other large investors have also recently made changes to their positions in the company. Bank of Nova Scotia bought a new position in Abbott Laboratories during the 2nd quarter valued at about $44,214,000. Vista Investment Management purchased a new position in shares of Abbott Laboratories during the second quarter valued at approximately $615,000. Elevation Point Wealth Partners LLC bought a new position in shares of Abbott Laboratories during the second quarter valued at approximately $4,642,000. Daiichi Life Insurance Co. Ltd. purchased a new stake in shares of Abbott Laboratories in the second quarter worth approximately $9,027,000. Finally, Foyston Gordon & Payne Inc bought a new stake in shares of Abbott Laboratories during the 2nd quarter worth approximately $1,107,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes Several equities analysts have commented on ABT shares. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $130.00 price objective on shares of Abbott Laboratories in a research report on Friday, July 17th. Citigroup boosted their target price on shares of Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a research note on Friday, July 17th. UBS Group reduced their price target on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. JPMorgan Chase & Co. lifted their price objective on shares of Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Finally, The Goldman Sachs Group lowered their price objective on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research report on Wednesday, May 27th. Three analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $119.50.

Check Out Our Latest Analysis on Abbott Laboratories Abbott Laboratories Stock Performance Shares of NYSE:ABT opened at $110.48 on Tuesday. The company has a market capitalization of $191.17 billion, a price-to-earnings ratio of 35.75, a price-to-earnings-growth ratio of 2.18 and a beta of 0.59. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The firm has a 50 day moving average of $103.06 and a 200 day moving average of $100.13.

Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The business had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business’s revenue was up 13.0% compared to the same quarter last year. During the same period last year, the business posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, sell-side analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement The company also recently declared a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is presently 81.55%.

Abbott Laboratories Profile (Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Featured Stories Five stocks we like better than Abbott Laboratories Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season Insiders Are Betting Big on These 3 Healthcare Stocks 3 Stocks for Investors Who Still Believe Cash Is King Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

EP Wealth Advisors LLC purchased a new position in shares of Abbott Laboratories (NYSE:ABT – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 79,164 shares of the healthcare product maker’s stock, valued at approximately $7,183,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ABT. BlackRock Inc. raised its stake in shares of Abbott Laboratories by 4.6% during the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock valued at $13,843,610,000 after purchasing an additional 6,769,518 shares during the period. State Street Corp boosted its stake in shares of Abbott Laboratories by 2.1% in the fourth quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker’s stock valued at $10,004,880,000 after purchasing an additional 1,627,791 shares during the period. Capital International Investors grew its holdings in Abbott Laboratories by 2.6% during the 4th quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock valued at $7,922,519,000 after purchasing an additional 1,614,706 shares in the last quarter. J. Stern & Co. LLP increased its stake in Abbott Laboratories by 12,439.6% during the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after buying an additional 39,005,451 shares during the period. Finally, Capital Research Global Investors lifted its holdings in Abbott Laboratories by 1.0% in the 4th quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker’s stock worth $4,907,523,000 after buying an additional 400,400 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades ABT has been the subject of several recent analyst reports. Piper Sandler restated an “overweight” rating and set a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Bank of America cut their price target on Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. JPMorgan Chase & Co. raised their price objective on Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Weiss Ratings upgraded Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, August 6th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $130.00 target price on shares of Abbott Laboratories in a research report on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $119.50.

View Our Latest Stock Report on ABT Abbott Laboratories Price Performance Shares of NYSE ABT opened at $110.48 on Tuesday. The company has a market capitalization of $191.17 billion, a price-to-earnings ratio of 35.75, a price-to-earnings-growth ratio of 2.18 and a beta of 0.59. The business has a 50 day simple moving average of $103.06 and a 200-day simple moving average of $100.13. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating the consensus estimate of $1.28 by $0.03. The business had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company’s quarterly revenue was up 13.0% on a year-over-year basis. During the same period in the previous year, the business posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities research analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend The business also recently announced a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were issued a dividend of $0.63 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio is 81.55%.

Abbott Laboratories Company Profile (Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Featured Stories Five stocks we like better than Abbott Laboratories Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season Insiders Are Betting Big on These 3 Healthcare Stocks 3 Stocks for Investors Who Still Believe Cash Is King Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

E Fund Management Co. Ltd. bought a new position in shares of Abbott Laboratories (NYSE:ABT – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 9,773 shares of the healthcare product maker’s stock, valued at approximately $887,000.

Several other hedge funds and other institutional investors have also bought and sold shares of ABT. J. Stern & Co. LLP boosted its stake in Abbott Laboratories by 12,439.6% in the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after acquiring an additional 39,005,451 shares during the last quarter. Norges Bank purchased a new position in Abbott Laboratories in the fourth quarter valued at approximately $2,938,892,000. Flossbach Von Storch SE bought a new position in Abbott Laboratories during the second quarter valued at $902,938,000. BlackRock Inc. raised its stake in shares of Abbott Laboratories by 4.6% in the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock valued at $13,843,610,000 after buying an additional 6,769,518 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its position in shares of Abbott Laboratories by 217.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 5,522,222 shares of the healthcare product maker’s stock valued at $566,967,000 after buying an additional 3,780,402 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Price Performance ABT stock opened at $112.63 on Monday. The firm has a 50 day moving average of $102.61 and a 200-day moving average of $100.14. The firm has a market capitalization of $194.89 billion, a P/E ratio of 36.45, a price-to-earnings-growth ratio of 2.18 and a beta of 0.59. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. During the same period in the prior year, the company posted $1.26 EPS. The business’s revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, sell-side analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year. Abbott Laboratories Dividend Announcement The firm also recently announced a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is currently 81.55%.

Trending Headlines about Abbott Laboratories Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: The FDA approved Abbott’s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients age two and older. The wearable is the first of its kind to track both glucose and ketones, strengthening Abbott’s position in diabetes care and creating potential for future integration with insulin-pump systems. FDA Approves Abbott’s First Wearable Device for Dual Ketone and Glucose Tracking Positive Sentiment: Abbott received the European CE Mark for its next-generation Amulet 360 left atrial appendage occluder. The device is designed to reduce stroke risk in certain atrial-fibrillation patients and may reduce reliance on blood-thinning medication, supporting growth in Abbott’s structural-heart business. Abbott’s next-generation Amulet 360 device receives CE Mark Positive Sentiment: Analyst coverage remains supportive, with TD Cowen expecting Abbott’s stock to rise. Separately, Zacks highlighted ABT as a strong long-term momentum candidate, suggesting improving price trends and investor interest despite its premium valuation. TD Cowen Analyst Says Abbott Stock Price Expected to Rise Neutral Sentiment: Abbott’s latest reported quarter exceeded consensus estimates, with earnings and revenue growing year over year. Management’s 2026 earnings guidance also points to continued expansion, but ABT’s elevated price-to-earnings ratio leaves the stock sensitive to execution and valuation concerns. Negative Sentiment: Recent coverage noted that Abbott shares fell 2.2% in the prior session even as the broader market advanced, reflecting near-term underperformance and possible profit-taking. The stock remains well below its 12-month high, so investors may want evidence that the new devices translate into meaningful sales growth. Abbott Stock Sinks as Market Gains Analyst Ratings Changes Several equities research analysts recently weighed in on ABT shares. The Goldman Sachs Group decreased their price objective on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a report on Wednesday, May 27th. Citigroup increased their target price on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. JPMorgan Chase & Co. boosted their price target on shares of Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. Bank of America dropped their price target on shares of Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Finally, Weiss Ratings upgraded shares of Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, August 6th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $119.50.

Check Out Our Latest Analysis on ABT

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Read More Five stocks we like better than Abbott Laboratories Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against? Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Callan Family Office LLC acquired a new stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 94,188 shares of the healthcare product maker’s stock, valued at approximately $8,547,000.

A number of other large investors have also added to or reduced their stakes in the stock. MidAtlantic Capital Management Inc. purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $25,000. Cornerstone Financial Management LLC purchased a new position in shares of Abbott Laboratories during the fourth quarter worth about $25,000. Purpose Unlimited Inc. purchased a new stake in Abbott Laboratories during the fourth quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in shares of Abbott Laboratories during the fourth quarter worth approximately $26,000. Finally, Abound Financial LLC purchased a new stake in Abbott Laboratories during the 4th quarter valued at about $26,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Up 0.1% Shares of ABT opened at $112.63 on Monday. The firm has a fifty day moving average price of $102.61 and a 200-day moving average price of $100.14. The firm has a market capitalization of $194.89 billion, a P/E ratio of 36.45, a P/E/G ratio of 2.18 and a beta of 0.59. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. During the same period in the prior year, the business earned $1.26 EPS. The business’s revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities research analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current year. Abbott Laboratories Dividend Announcement The company also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were given a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. Abbott Laboratories’s payout ratio is presently 81.55%.

Analysts Set New Price Targets Several research firms have weighed in on ABT. TD Cowen increased their price objective on Abbott Laboratories from $115.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, August 25th. Royal Bank Of Canada restated an “outperform” rating and set a $130.00 target price on shares of Abbott Laboratories in a research note on Friday, July 17th. UBS Group cut their price target on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Wells Fargo & Company upped their price target on Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Finally, Piper Sandler reissued an “overweight” rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $119.50.

Read Our Latest Analysis on ABT

Trending Headlines about Abbott Laboratories Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: The FDA approved Abbott’s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients age two and older. The wearable is the first of its kind to track both glucose and ketones, strengthening Abbott’s position in diabetes care and creating potential for future integration with insulin-pump systems. FDA Approves Abbott’s First Wearable Device for Dual Ketone and Glucose Tracking Positive Sentiment: Abbott received the European CE Mark for its next-generation Amulet 360 left atrial appendage occluder. The device is designed to reduce stroke risk in certain atrial-fibrillation patients and may reduce reliance on blood-thinning medication, supporting growth in Abbott’s structural-heart business. Abbott’s next-generation Amulet 360 device receives CE Mark Positive Sentiment: Analyst coverage remains supportive, with TD Cowen expecting Abbott’s stock to rise. Separately, Zacks highlighted ABT as a strong long-term momentum candidate, suggesting improving price trends and investor interest despite its premium valuation. TD Cowen Analyst Says Abbott Stock Price Expected to Rise Neutral Sentiment: Abbott’s latest reported quarter exceeded consensus estimates, with earnings and revenue growing year over year. Management’s 2026 earnings guidance also points to continued expansion, but ABT’s elevated price-to-earnings ratio leaves the stock sensitive to execution and valuation concerns. Negative Sentiment: Recent coverage noted that Abbott shares fell 2.2% in the prior session even as the broader market advanced, reflecting near-term underperformance and possible profit-taking. The stock remains well below its 12-month high, so investors may want evidence that the new devices translate into meaningful sales growth. Abbott Stock Sinks as Market Gains (Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Read More Five stocks we like better than Abbott Laboratories Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against? Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Fairtree Asset Management Pty Ltd purchased a new position in shares of Abbott Laboratories (NYSE:ABT – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 21,856 shares of the healthcare product maker’s stock, valued at approximately $1,983,000.

Several other large investors have also made changes to their positions in the business. BlackRock Inc. raised its holdings in shares of Abbott Laboratories by 4.6% during the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock worth $13,843,610,000 after purchasing an additional 6,769,518 shares during the last quarter. State Street Corp boosted its holdings in Abbott Laboratories by 2.1% in the fourth quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker’s stock valued at $10,004,880,000 after purchasing an additional 1,627,791 shares during the last quarter. Capital International Investors grew its position in Abbott Laboratories by 2.6% during the 4th quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock worth $7,922,519,000 after purchasing an additional 1,614,706 shares during the period. J. Stern & Co. LLP grew its position in Abbott Laboratories by 12,439.6% during the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after purchasing an additional 39,005,451 shares during the period. Finally, Capital Research Global Investors raised its stake in shares of Abbott Laboratories by 1.0% during the 4th quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker’s stock valued at $4,907,523,000 after buying an additional 400,400 shares during the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Price Performance NYSE:ABT opened at $112.63 on Monday. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The stock’s 50-day moving average price is $102.61 and its 200-day moving average price is $100.14. The stock has a market capitalization of $194.89 billion, a PE ratio of 36.45, a price-to-earnings-growth ratio of 2.18 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter in the prior year, the business posted $1.26 earnings per share. Abbott Laboratories’s revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities analysts expect that Abbott Laboratories will post 5.52 EPS for the current fiscal year. Abbott Laboratories Announces Dividend The business also recently declared a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were paid a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 81.55%.

Analyst Ratings Changes A number of brokerages have recently commented on ABT. UBS Group lowered their target price on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. Robert W. Baird began coverage on Abbott Laboratories in a report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price target for the company. Bank of America lowered their price objective on Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. TD Cowen raised their price objective on shares of Abbott Laboratories from $115.00 to $135.00 and gave the stock a “buy” rating in a research note on Tuesday, August 25th. Finally, Weiss Ratings raised shares of Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, August 6th. Three analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $119.50.

View Our Latest Stock Report on ABT

Abbott Laboratories News Roundup Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: The FDA approved Abbott’s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients age two and older. The wearable is the first of its kind to track both glucose and ketones, strengthening Abbott’s position in diabetes care and creating potential for future integration with insulin-pump systems. FDA Approves Abbott’s First Wearable Device for Dual Ketone and Glucose Tracking Positive Sentiment: Abbott received the European CE Mark for its next-generation Amulet 360 left atrial appendage occluder. The device is designed to reduce stroke risk in certain atrial-fibrillation patients and may reduce reliance on blood-thinning medication, supporting growth in Abbott’s structural-heart business. Abbott’s next-generation Amulet 360 device receives CE Mark Positive Sentiment: Analyst coverage remains supportive, with TD Cowen expecting Abbott’s stock to rise. Separately, Zacks highlighted ABT as a strong long-term momentum candidate, suggesting improving price trends and investor interest despite its premium valuation. TD Cowen Analyst Says Abbott Stock Price Expected to Rise Neutral Sentiment: Abbott’s latest reported quarter exceeded consensus estimates, with earnings and revenue growing year over year. Management’s 2026 earnings guidance also points to continued expansion, but ABT’s elevated price-to-earnings ratio leaves the stock sensitive to execution and valuation concerns. Negative Sentiment: Recent coverage noted that Abbott shares fell 2.2% in the prior session even as the broader market advanced, reflecting near-term underperformance and possible profit-taking. The stock remains well below its 12-month high, so investors may want evidence that the new devices translate into meaningful sales growth. Abbott Stock Sinks as Market Gains Abbott Laboratories Profile (Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

See Also Five stocks we like better than Abbott Laboratories Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against? Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Libre Duo 10 Day is a first-of-its-kind, two-in-one biowearable that monitors glucose and helps detect rising ketone levels that can lead to diabetic ketoacidosis (DKA), a serious health condition for people living with diabetes Designed to seamlessly address a critical gap in ketone monitoring, providing needed health data without adding burden on people living with diabetes Integrates with the latest-generation Libre app available in the U.S. and the full Libre digital health ecosystem; designed for compatibility with leading automated insulin delivery (AID) systems , /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, today announced U.S. Food and Drug Administration (FDA) authorization of its Libre Duo 10 Day system, the world's first dual glucose‑ketone sensing technology. The new biowearable is designed to alert people living with diabetes of rising ketones that can lead to a diabetic ketoacidosis (DKA) emergency, a serious health complication for people with diabetes. Libre Duo 10 Day delivers real-time visibility into glucose levels needed for daily diabetes management while also monitoring rising ketones in the background, avoiding additional mental or physical burden for people with diabetes. Abbott plans to launch Libre Duo 10 Day in the United States later this year.

Abbott receives FDA authorization for world’s first dual glucose-ketone sensing technology for people with diabetes

Abbott receives FDA authorization for world’s first dual glucose-ketone sensing technology for people with diabetes First-of-its-kind technology

Libre Duo 10 Day received De Novo authorization after securing breakthrough device designation from the FDA through a program designed to help people gain faster access to innovative medical technologies. It's the first system to meet the FDA's integrated continuous glucose monitoring (iCGM) standard and the new integrated continuous glucose and ketone monitoring (iCGK) standard, which establishes a benchmark for continuous ketone monitoring in the United States.

Monitoring ketones in the background

DKA is the most common hyperglycemic emergency for people living with diabetes,1,2 and hospital admissions for DKA have increased 55% over the past decade.3 DKA can develop quickly when the body does not have enough insulin and then starts to break down fat for energy, causing ketone levels to rise to potentially dangerous levels in the blood.4  According to the American Diabetes Association, DKA can progress within hours and, if left untreated, can lead to coma or death.4 While clinical guidance is to test ketones during illness or periods of elevated glucose, the majority of people do not have access to a blood ketone meter at home5 and early signs of rising ketones are often mistaken for common infections, resulting in delayed treatment .2,6,7

"As a physician, I see how quickly DKA can develop—and how often early warning signs or opportunities to measure ketones are missed," said Jennifer Sherr, M.D., Ph.D., pediatric endocrinologist at Yale School of Medicine. "Abbott's dual glucose-ketone system is meaningful because ketone data is collected in the background, helping provide earlier awareness of rising ketone levels."  

How Libre Duo 10 Day works

Libre Duo 10 Day continuously monitors both glucose – the standard of care for daily diabetes management – and ketone levels. Unlike blood or urine ketone tests, which provide only a single point-in-time reading, the sensors continuously track ketones and are designed to alert people when ketones are rising.

"If glucose is the speedometer, ketones are like the check engine light—providing an alert that something may need attention," said Chris Scoggins, executive vice president of Abbott's diabetes care business. "Libre Duo 10 Day brings both glucose and ketone levels together in a single dashboard, providing a more complete picture to help people with diabetes make more informed decisions."

Libre Duo 10 Day is designed for those who may be at higher risk of elevated ketones. This includes people with Type 1 or Type 2 diabetes who use insulin or other glucose-lowering medications, such as sodium-glucose cotransporter 2 inhibitors, also known as SGLT2s.

Libre Duo 10 Day offers up to 10 days of wear8 and is intended for people with diabetes ages 2 and older. It uses the latest-generation Libre app available in the United States today and will integrate with the broader Libre digital health ecosystem, including LibreView for health care providers and LibreLinkUp for caregivers.

Abbott is working with leading pump companies to enable automated insulin delivery (AID) systems to connect with the sensors. The company expects Libre Duo 10 Day to work with Beta Bionics' iLet and Sequel Med Tech's twiist AID systems by the end of this year and with devices from Insulet and Tandem in 2027. Abbott and MiniMed are collaborating on an exclusive integration between Abbott-manufactured dual glucose-ketone sensors and MiniMed smart dosing systems, which is expected in 2027.

"In my role with Breakthrough T1D, and as someone who has lived with Type 1 diabetes for decades, I understand the serious risk of diabetic ketoacidosis and how challenging it can be to identify and monitor elevated ketone levels," said Aaron J. Kowalski, Ph.D., chief executive officer of Breakthrough T1D. "New technology like Abbott's dual glucose-ketone system has the potential to change that reality by giving people early and actionable information that can help identify and prevent dangerous complications like DKA. Breakthrough T1D is excited that the diabetes community will have this option available to support their day-to-day management."

Abbott received CE Mark for Libre Duo systems earlier this year.

For more about Libre Duo 10 Day, visit https://abbo.tt/libreduo.

Frequently Asked Questions

Do people with diabetes need a continuous ketone monitor?
Continuous glucose monitors (CGMs) track glucose, but they do not measure ketones. According to the American Diabetes Association, elevated ketones can progress to diabetic ketoacidosis (DKA) within hours, making early detection critical. Because ketone levels can rise quickly — sometimes independently of glucose and differently for each person — and symptoms are often mistaken for common illnesses, having an alert system helps people act sooner.4,6,9,7

Can ketones be elevated even when glucose is normal?

DKA can still develop even when glucose levels appear stable6. While CGMs play an essential role in helping people manage their diabetes, they do not currently measure ketones, which are the key driver of DKA. Relying on glucose data alone may not always provide an early warning before DKA develops, which is why a dual glucose-ketone sensor, like Libre Duo 10 Day in the United States, can provide useful information for people living with diabetes.

How will people know when to take action?  

Similar to how CGMs help with glucose, Abbott's Libre Duo 10 Day will operate in the background, and alert people when ketone levels are elevated. Libre Duo 10 day is designed to provide important information when people need it.

About Libre:

Abbott is the global leader in diabetes technology and biowearables. More than 10 years ago, Abbott transformed diabetes care with its world-leading Libre continuous glucose monitoring portfolio, now used by more than 8 million people in over 60 countries10. Libre technology provides real-time, personalized insights to help people understand how food, activity and medications affect their bodies. The latest Libre innovation is the world's first dual glucose-ketone sensor, which monitors glucose and helps detect rising ketone levels that can lead to diabetic ketoacidosis, a serious diabetes-related complication.

About Abbott:

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X, and YouTube.

Important Safety Information (for U.S. residents only):

Failure to use the Libre Duo 10 Day system as instructed in labeling may result in missing a severe glucose and/or ketones event and/or making a treatment decision, resulting in injury. If readings and alarms (if enabled) do not match symptoms or expectations, use a fingerstick glucose value from a blood glucose meter for treatment decisions. Ketone output should be used in conjunction with glucose levels. The Urgent Low Glucose alarm and Urgent High Ketones alarm may not detect all instances of glucose less than 55 mg/dL and ketones higher than 3.0 mmol/L, so these should be used together with respective sensor readings for treatment decisions. Get medical attention when appropriate. For more information, call Abbott Customer Service at 855-632-8658 or visit FreeStyleLibre.us.

Centers for Disease Control. "National Diabetes Statistics Report." Accessed May 4, 2026. National Diabetes Statistics Report - United States Diabetes Surveillance System Nguyen, K. T. Journal of Diabetes Science and Technology (2022). https://doi.org/10.1177/19322968211042656. Umpierrez, et al. Diabetes Care (2024): https://doi.org/10.2337/dci24-0032. American Diabetes Association. "Planning for Sick Days." Accessed February 6, 2026. https://diabetes.org/getting-sick-with-diabetes/sick-days. Albanese-O'Neill et al. Diabetes Care (2017): https://doi.org/10.2337/dc16-2620. Dhatariya, et al. Lancet Diabetes & Endocrinology (2025): https://pubmed.ncbi.nlm.nih.gov/41381175/ Virdi, N. Diabetes Technology & Therapeutics (2023). https://doi.org/10.1089/dia.2023.0149. A study was conducted to evaluate Libre Duo 10 Day sensor wear duration. Results showed that 84.1% of sensors in the adult population and 68.8% of sensors in the pediatric population lasted the full 10 days. This means that, when the product is used according to the labeling, approximately 16% of sensors in the adult population and 31% of sensors in the pediatric population may not last for the full 10 days. Seidu S. et al. 'Rising burden of diabetic ketoacidosis in the UK: 23-year trends, recurrence, and predictors from linked primary–secondary care data.' Oral presentation, ATTD 2026, Barcelona, Spain, 11-14 March 2026. Data on File, Abbott Diabetes Care. Data based on the number of patients assigned to each manufacturer. SOURCE Abbott

The U.S. Food and Drug Administration said on Tuesday it authorized Abbott Laboratories' (ABT.N) glucose monitor, making it ​the first device that continuously monitors both ketone ‌levels and blood sugar.

Here are some details:

The device branded as Libre Duo 10 Day is designed for a 10-day wear period for ​people aged 2 years and older living with ​diabetes.

The biowearable is designed to alert people of ⁠rising ketones that can lead to a diabetic ketoacidosis (DKA) ​emergency, a serious health complication for people with diabetes.

Unlike earlier ​ketone tests that offered only separate, one-time readings, Abbott's device continuously monitors both ketone and glucose levels, displaying real-time trends.

The device can ​send automatic alerts, which may help patients and caregivers ​recognize rising ketones before DKA becomes a medical emergency.

"If glucose is ‌the ⁠speedometer, ketones are like the check engine light—providing an alert that something may need attention," said Chris Scoggins, executive vice president of Abbott's diabetes care business.

The device brings both ​glucose and ​ketone levels ⁠together in a single dashboard, providing a more complete picture to help people with diabetes ​make more informed decisions, added Scoggins.

Abbott is ​working ⁠with leading pump companies to enable automated insulin delivery systems to connect with the sensors.

The company said the device integrates ⁠with ​the Libre app and expects Libre ​Duo 10 Day to work with devices from Insulet and Tandem in ​2027.

Bank of New York Mellon Corp lessened its stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 19.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,991,899 shares of the healthcare product maker’s stock after selling 2,450,818 shares during the quarter. Bank of New York Mellon Corp owned about 0.58% of Abbott Laboratories worth $906,665,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Freemont Management S.A. grew its stake in shares of Abbott Laboratories by 197.2% in the 4th quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock valued at $1,341,000 after purchasing an additional 7,100 shares during the last quarter. PFA Pension Forsikringsaktieselskab purchased a new stake in shares of Abbott Laboratories during the fourth quarter worth approximately $116,580,000. Thrivent Financial for Lutherans lifted its holdings in shares of Abbott Laboratories by 24.3% during the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock worth $30,931,000 after purchasing an additional 48,286 shares during the period. Aureus Asset Management LLC grew its position in Abbott Laboratories by 25.0% in the 1st quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker’s stock valued at $34,078,000 after buying an additional 66,422 shares during the last quarter. Finally, North Dakota State Investment Board purchased a new position in Abbott Laboratories in the 4th quarter valued at $7,439,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories News Summary Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: The FDA authorized Abbott’s Libre Duo 10 Day, the first U.S. wearable designed to continuously monitor both glucose and ketone levels. The device is intended to help detect rising ketones associated with diabetic ketoacidosis and integrates with Abbott’s Libre app, digital-health ecosystem and compatible automated insulin-delivery systems. The approval strengthens Abbott’s continuous glucose-monitoring franchise and could expand its addressable market. Reuters FDA authorization article Positive Sentiment: TD Cowen raised its price target for ABT from $115 to $135 and maintained a “buy” rating, implying approximately 18% upside from the referenced $114.11 level. The target increase reflects confidence in Abbott’s growth prospects and valuation relative to peers. Benzinga analyst price target report Neutral Sentiment: Industry forecasts identify Abbott as a participant in expanding atrial-fibrillation treatment and device markets, particularly pulsed-field ablation, mapping catheters and left-atrial-appendage closure. These reports point to long-term opportunity but do not provide new Abbott-specific financial guidance. Atrial fibrillation treatment devices market report Negative Sentiment: Abbott agreed to pay $670 million to settle claims that its specialized premature-infant formula contributed to necrotizing enterocolitis. The settlement removes some litigation uncertainty but highlights continuing legal and financial risks. Abbott formula claims settlement article Wall Street Analyst Weigh In A number of brokerages have commented on ABT. Wolfe Research upgraded shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective for the company in a research report on Thursday, August 13th. Royal Bank Of Canada reiterated an “outperform” rating and set a $130.00 price target on shares of Abbott Laboratories in a research note on Friday, July 17th. BTIG Research increased their target price on Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Robert W. Baird began coverage on Abbott Laboratories in a research note on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price target on the stock. Finally, Wells Fargo & Company increased their price objective on Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $119.50. Get Our Latest Stock Analysis on ABT

Abbott Laboratories Trading Down 1.7% Shares of ABT stock opened at $114.11 on Thursday. The stock has a market cap of $197.45 billion, a P/E ratio of 36.93, a P/E/G ratio of 2.25 and a beta of 0.59. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The business has a fifty day simple moving average of $101.66 and a 200-day simple moving average of $100.13.

Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter in the prior year, the firm posted $1.26 earnings per share. The company’s quarterly revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were issued a dividend of $0.63 per share. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. Abbott Laboratories’s dividend payout ratio (DPR) is 81.55%.

Abbott Laboratories Profile (Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Further Reading Five stocks we like better than Abbott Laboratories Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise Alcoa’s Gallium Project Opens a New Door Beyond Aluminum Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech Can Tesla’s Flying Roadster Distract From Its Real Risks?

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Abbott just scored a regulatory first in diabetes care that no rival has matched, yet the stock sits well below where it traded a year ago. The real question is what it will actually take to close that gap.

On August 25, 2026, Abbott Laboratories (NYSE:ABT | ABT Price Prediction) received FDA De Novo authorization for the Libre Duo 10 Day, the first wearable cleared to continuously monitor glucose and detect rising ketone levels that can precede diabetic ketoacidosis.

De Novo is the pathway the FDA uses for novel low-to-moderate-risk devices that have no existing predicate. It marks a regulatory milestone that precedes any revenue impact.

The headline calls the stock beaten down, and the data mostly supports that framing. Abbott is down 11.29% over the past year and 7.25% year to date, though shares have rallied 9.2% over the past month to $114.10. The question is whether Libre Duo can push that recovery into a real re-rating.

What the FDA Cleared Libre Duo is described by Abbott as “the world’s first dual glucose ketone wearable sensor.” Ketoacidosis can develop within hours, so an early warning built into the same patch that already tracks glucose is a genuine clinical distinction.

Abbott plans a U.S. launch later in 2026 for patients ages 2 and older, entering an ecosystem already used by more than 8 million people. Planned integrations with insulin pumps from Beta Bionics, Sequel, Insulet, Tandem and MiniMed are not yet live.

CE Mark came in May, and CEO Robert Ford said U.S. discussions were in “very, very advanced kind of final stages” on the Q2 call. The authorization confirms that timeline.

Is the Stock Actually Cheap Enough to Re-Rate Abbott trades at a forward P/E of 21x against an analyst target of $120.20. That is a reasonable, though not distressed, multiple for a business raising full-year adjusted EPS guidance to $5.45 to $5.60.

Q2 CGM sales reached $2.188 billion, growing 9.5% comparable. Ford pushed back directly on the deceleration narrative: “I loved your characterization of only 9.5% on a $2 billion quarterly business.”

Meanwhile, Dexcom (NASDAQ:DXCM) shares are up 34.04% year to date, so the market has already rewarded the competitor. That gap sets up a catch-up trade if Libre Duo executes.

Where the Moat Actually Widens The real leverage is reimbursement. Ford said reimbursement expansion “drastically accelerates” growth, and potential U.S. Type 2 coverage could reach around 10 million Medicare beneficiaries.

Ketone detection matters most for Type 1 patients and insulin-pump users, which is why the planned pump integrations are the commercial hinge. Until those go live, Libre Duo is a differentiator on the shelf rather than in the workflow.

My view is that this authorization is meaningful but insufficient on its own to warrant a re-rate of the stock. It becomes a catalyst when pump partners ship integrated systems, and CMS moves on broader Type 2 coverage, both events Ford flagged as possible in the fall.

Watch the Q3 report on adjusted EPS guidance of $1.38 to $1.46 and any reimbursement announcement. Those are the events that would convert first-mover status into durable earnings power.

Contact [email protected] for any questions or corrections.

AMG National Trust Bank decreased its stake in Abbott Laboratories (NYSE:ABT – Free Report) by 30.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 31,489 shares of the healthcare product maker’s stock after selling 13,890 shares during the period. AMG National Trust Bank’s holdings in Abbott Laboratories were worth $2,857,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Cornerstone Financial Management LLC bought a new position in shares of Abbott Laboratories in the 4th quarter worth about $25,000. MidAtlantic Capital Management Inc. acquired a new position in shares of Abbott Laboratories during the fourth quarter valued at about $25,000. Purpose Unlimited Inc. bought a new stake in shares of Abbott Laboratories during the fourth quarter worth about $25,000. Portfolio Resources Advisor Group Inc. acquired a new stake in shares of Abbott Laboratories in the 4th quarter worth about $26,000. Finally, Abound Financial LLC bought a new position in Abbott Laboratories in the 4th quarter valued at about $26,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Price Performance ABT opened at $111.46 on Friday. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The firm has a 50-day moving average of $102.12 and a 200 day moving average of $100.13. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The firm has a market cap of $192.87 billion, a P/E ratio of 36.07, a PEG ratio of 2.21 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. During the same quarter in the previous year, the firm posted $1.26 earnings per share. The company’s revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, research analysts expect that Abbott Laboratories will post 5.52 EPS for the current year. Abbott Laboratories Announces Dividend The company also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were paid a $0.63 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio is presently 81.55%.

Abbott Laboratories News Summary Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: The FDA authorized Abbott’s Libre Duo 10 Day, the first U.S. wearable designed to continuously monitor both glucose and ketones. The device is cleared for diabetes patients age two and older and could strengthen Abbott’s Libre franchise, particularly as the company works toward integration with insulin pumps. What Does Abbott Laboratories FDA Clearance Mean for Its Diabetes Device Push? Positive Sentiment: Abbott received the European CE Mark for its next-generation Amulet 360 left atrial appendage occluder. The device is intended to reduce stroke risk in patients with non-valvular atrial fibrillation and may reduce reliance on blood-thinning medication. Recent trial data reportedly met safety and effectiveness benchmarks, supporting Abbott’s structural-heart and electrophysiology businesses. Abbott Amulet 360 Receives CE Mark Positive Sentiment: TD Cowen analyst commentary indicated that Abbott’s stock could rise, providing an additional vote of confidence in the company’s outlook. TD Cowen Says Abbott Stock Could Rise Neutral Sentiment: The regulatory approvals are strategically important, but their financial benefits will depend on commercial adoption, reimbursement, competitive responses and the timing of integration with insulin-pump systems. Negative Sentiment: Abbott underperformed while the broader market gained. The pullback suggests that investors may be focusing on the stock’s relatively high valuation and the fact that the newly approved products are longer-term growth catalysts rather than immediate earnings drivers. Why Abbott Stock Declined as the Market Gained Analysts Set New Price Targets ABT has been the subject of a number of recent research reports. JPMorgan Chase & Co. boosted their price objective on Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. Weiss Ratings upgraded Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, August 6th. The Goldman Sachs Group lowered their price target on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research report on Wednesday, May 27th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $130.00 price objective on shares of Abbott Laboratories in a report on Friday, July 17th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat, Abbott Laboratories has an average rating of “Moderate Buy” and an average target price of $119.50.

Check Out Our Latest Stock Report on Abbott Laboratories

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Featured Articles Five stocks we like better than Abbott Laboratories Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape SEC Probe Puts Wall Street Leverage Risk Back in Focus A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

BlackRock Inc. increased its holdings in Abbott Laboratories (NYSE:ABT – Free Report) by 4.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 152,563,476 shares of the healthcare product maker’s stock after acquiring an additional 6,769,518 shares during the period. BlackRock Inc. owned approximately 8.82% of Abbott Laboratories worth $13,843,610,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. MidAtlantic Capital Management Inc. acquired a new position in Abbott Laboratories in the fourth quarter valued at approximately $25,000. Cornerstone Financial Management LLC acquired a new stake in Abbott Laboratories during the fourth quarter worth approximately $25,000. Purpose Unlimited Inc. purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in shares of Abbott Laboratories in the 4th quarter valued at $26,000. Finally, Abound Financial LLC acquired a new position in Abbott Laboratories in the fourth quarter valued at $26,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance ABT opened at $112.63 on Friday. The stock’s 50 day simple moving average is $102.61 and its 200 day simple moving average is $100.22. The stock has a market cap of $194.89 billion, a P/E ratio of 36.45, a P/E/G ratio of 2.16 and a beta of 0.59. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. The company had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.Abbott Laboratories’s revenue was up 13.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current fiscal year. Abbott Laboratories Dividend Announcement The firm also recently declared a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were given a $0.63 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. Abbott Laboratories’s dividend payout ratio is currently 81.55%.

Trending Headlines about Abbott Laboratories Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: The FDA approved Abbott’s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients age two and older. The wearable is the first of its kind to track both glucose and ketones, strengthening Abbott’s position in diabetes care and creating potential for future integration with insulin-pump systems. FDA Approves Abbott’s First Wearable Device for Dual Ketone and Glucose Tracking Positive Sentiment: Abbott received the European CE Mark for its next-generation Amulet 360 left atrial appendage occluder. The device is designed to reduce stroke risk in certain atrial-fibrillation patients and may reduce reliance on blood-thinning medication, supporting growth in Abbott’s structural-heart business. Abbott’s next-generation Amulet 360 device receives CE Mark Positive Sentiment: Analyst coverage remains supportive, with TD Cowen expecting Abbott’s stock to rise. Separately, Zacks highlighted ABT as a strong long-term momentum candidate, suggesting improving price trends and investor interest despite its premium valuation. TD Cowen Analyst Says Abbott Stock Price Expected to Rise Neutral Sentiment: Abbott’s latest reported quarter exceeded consensus estimates, with earnings and revenue growing year over year. Management’s 2026 earnings guidance also points to continued expansion, but ABT’s elevated price-to-earnings ratio leaves the stock sensitive to execution and valuation concerns. Negative Sentiment: Recent coverage noted that Abbott shares fell 2.2% in the prior session even as the broader market advanced, reflecting near-term underperformance and possible profit-taking. The stock remains well below its 12-month high, so investors may want evidence that the new devices translate into meaningful sales growth. Abbott Stock Sinks as Market Gains Wall Street Analyst Weigh In Several analysts have recently weighed in on the company. Royal Bank Of Canada reissued an “outperform” rating and issued a $130.00 target price on shares of Abbott Laboratories in a report on Friday, July 17th. Weiss Ratings raised Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, August 6th. Bank of America lowered their target price on shares of Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Robert W. Baird began coverage on shares of Abbott Laboratories in a research report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price target for the company. Finally, Citigroup increased their target price on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $119.50.

View Our Latest Report on ABT

Abbott Laboratories Profile (Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Featured Articles Five stocks we like better than Abbott Laboratories 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude? Okta Stock Surges 29%—Is $200 the Next Stop? Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Frazier Financial Advisors LLC bought a new stake in Abbott Laboratories (NYSE:ABT – Free Report) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 27,113 shares of the healthcare product maker’s stock, valued at approximately $2,460,000. Abbott Laboratories comprises about 1.2% of Frazier Financial Advisors LLC’s holdings, making the stock its 11th largest position.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Cornerstone Financial Management LLC purchased a new position in shares of Abbott Laboratories during the fourth quarter worth about $25,000. MidAtlantic Capital Management Inc. purchased a new stake in shares of Abbott Laboratories in the 4th quarter valued at about $25,000. Purpose Unlimited Inc. acquired a new stake in shares of Abbott Laboratories in the 4th quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in Abbott Laboratories during the 4th quarter worth approximately $26,000. Finally, Abound Financial LLC purchased a new position in Abbott Laboratories during the 4th quarter worth approximately $26,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In ABT has been the subject of a number of research reports. Wells Fargo & Company boosted their price objective on Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. TD Cowen lifted their target price on shares of Abbott Laboratories from $115.00 to $135.00 and gave the company a “buy” rating in a report on Tuesday, August 25th. Weiss Ratings upgraded shares of Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, August 6th. Wolfe Research raised shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective on the stock in a research report on Thursday, August 13th. Finally, Bank of America dropped their price objective on shares of Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $119.50.

View Our Latest Stock Report on ABT Key Abbott Laboratories News Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: The FDA approved Abbott’s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients age two and older. The wearable is the first of its kind to track both glucose and ketones, strengthening Abbott’s position in diabetes care and creating potential for future integration with insulin-pump systems. FDA Approves Abbott’s First Wearable Device for Dual Ketone and Glucose Tracking Positive Sentiment: Abbott received the European CE Mark for its next-generation Amulet 360 left atrial appendage occluder. The device is designed to reduce stroke risk in certain atrial-fibrillation patients and may reduce reliance on blood-thinning medication, supporting growth in Abbott’s structural-heart business. Abbott’s next-generation Amulet 360 device receives CE Mark Positive Sentiment: Analyst coverage remains supportive, with TD Cowen expecting Abbott’s stock to rise. Separately, Zacks highlighted ABT as a strong long-term momentum candidate, suggesting improving price trends and investor interest despite its premium valuation. TD Cowen Analyst Says Abbott Stock Price Expected to Rise Neutral Sentiment: Abbott’s latest reported quarter exceeded consensus estimates, with earnings and revenue growing year over year. Management’s 2026 earnings guidance also points to continued expansion, but ABT’s elevated price-to-earnings ratio leaves the stock sensitive to execution and valuation concerns. Negative Sentiment: Recent coverage noted that Abbott shares fell 2.2% in the prior session even as the broader market advanced, reflecting near-term underperformance and possible profit-taking. The stock remains well below its 12-month high, so investors may want evidence that the new devices translate into meaningful sales growth. Abbott Stock Sinks as Market Gains Abbott Laboratories Price Performance Shares of NYSE ABT opened at $112.63 on Friday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The firm has a market capitalization of $194.89 billion, a P/E ratio of 36.45, a PEG ratio of 2.18 and a beta of 0.59. The company’s fifty day moving average is $102.61 and its two-hundred day moving average is $100.22.

Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter last year, the firm posted $1.26 EPS. The business’s revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Analysts forecast that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement The business also recently declared a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 81.55%.

Abbott Laboratories Profile (Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Read More Five stocks we like better than Abbott Laboratories From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash Venture Into High-Volatility Corners of the Market With These 3 ETFs 3 Retail Stocks to Watch After a Big Consumer Earnings Week Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Choreo LLC cut its position in Abbott Laboratories (NYSE:ABT – Free Report) by 4.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 100,143 shares of the healthcare product maker’s stock after selling 4,580 shares during the quarter. Choreo LLC’s holdings in Abbott Laboratories were worth $9,087,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in ABT. Freemont Management S.A. lifted its position in Abbott Laboratories by 197.2% in the fourth quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock worth $1,341,000 after purchasing an additional 7,100 shares during the period. PFA Pension Forsikringsaktieselskab bought a new stake in Abbott Laboratories in the 4th quarter valued at $116,580,000. Thrivent Financial for Lutherans raised its stake in shares of Abbott Laboratories by 24.3% in the 4th quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock valued at $30,931,000 after buying an additional 48,286 shares in the last quarter. Aureus Asset Management LLC lifted its holdings in shares of Abbott Laboratories by 25.0% during the 1st quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker’s stock worth $34,078,000 after acquiring an additional 66,422 shares during the period. Finally, North Dakota State Investment Board acquired a new stake in shares of Abbott Laboratories during the 4th quarter valued at about $7,439,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Stock Up 0.1% NYSE ABT opened at $116.70 on Tuesday. The stock’s 50 day simple moving average is $100.64 and its 200 day simple moving average is $100.03. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The firm has a market cap of $201.94 billion, a PE ratio of 37.77, a price-to-earnings-growth ratio of 2.26 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97.

Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, sell-side analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year. Abbott Laboratories Dividend Announcement The business also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.2%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 81.55%.

Wall Street Analyst Weigh In ABT has been the subject of several recent research reports. TD Cowen reissued a “buy” rating and issued a $115.00 price target on shares of Abbott Laboratories in a research report on Friday, July 17th. Wolfe Research upgraded Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective on the stock in a research note on Thursday, August 13th. BTIG Research raised their target price on Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. Bank of America decreased their price target on Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a $130.00 price objective on shares of Abbott Laboratories in a research note on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $118.67.

View Our Latest Analysis on Abbott Laboratories

Abbott Laboratories News Summary Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: New diabetes-device opportunity: Medtronic has begun shipping its MiniMed Flex insulin pump, which uses an Abbott-made glucose sensor. The launch and accompanying marketing campaign could expand Abbott’s sensor presence in the growing diabetes-care market. MiniMed starts shipping new insulin pump with Abbott-made sensor Positive Sentiment: Underlying business remains diversified: Analyst commentary highlights Abbott’s established diagnostics, medical-device and nutrition franchises, along with long-term growth opportunities. Its latest reported quarter also exceeded consensus earnings and revenue estimates, with revenue up 13% year over year. Ken Griffin Just Loaded Up on AbbVie and Abbott Neutral Sentiment: Formula litigation clarity: Abbott agreed to pay approximately $670 million to resolve the Gill case and about 2,000 additional necrotizing-enterocolitis claims without admitting liability. The settlement is costly, but it removes uncertainty tied to a large jury award and provides greater visibility into remaining litigation exposure. How Investors Are Reacting To Abbott Laboratories US$670 Million NEC Settlement Neutral Sentiment: Investor comparisons are favorable but valuation-sensitive: Articles describe Abbott as a potential long-term healthcare and dividend investment, though comparisons with Envista, Intuitive Surgical, Thermo Fisher and Johnson & Johnson emphasize differing growth, recovery and valuation profiles. NVST or ABT: Which Is the Better Value Stock Right Now? Negative Sentiment: Diagnostics growth is uneven: Weaker respiratory-testing demand is offsetting healthy routine testing and approximately 13% growth in cancer diagnostics. This mix could moderate near-term Diagnostics momentum despite strength in higher-growth categories. Here’s What Is Shaping Abbott’s Diagnostics Growth Abbott Laboratories Profile (Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Featured Stories Five stocks we like better than Abbott Laboratories Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain Snowflake Could Be Headed for New Highs Despite Insider Selling MongoDB Is Surging—And the Next Catalyst Is Almost Here

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.